Comprehensive expression profile of long non-coding RNAs in Peripheral blood mononuclear cells from patients with neuropsychiatric systemic lupus erythematosus.

Long non-coding RNA co-expression networks gene ontology terms kyoto encyclopedia of genes and genomes neuropsychiatric systemic lupus erythematosus (NPSLE)

Journal

Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978

Informations de publication

Date de publication:
Mar 2020
Historique:
entrez: 2 5 2020
pubmed: 2 5 2020
medline: 2 5 2020
Statut: ppublish

Résumé

Long noncoding RNAs (lncRNAs) are emerging as critical regulators of gene expression in the immune system, but their impact on neuropsychiatric systemic lupus erythematosus (NPSLE) remains unknown. RNA sequencing analysis was used to screen the comprehensive expression profile of lncRNAs and messenger RNAs (mRNAs) in peripheral blood mononuclear cells (PBMCs) from NPSLE patients, active SLE patients who had never experienced neuropsychiatric manifestations (Non-NPSLE) and healthy controls. Differentially expressed (DE) lncRNA levels were validated by qRT-PCR in 26 NPSLE patients, 31 Non-NPSLE patients and 30 healthy controls. Further, correlations of DE lncRNAs with clinical manifestations of NPSLE patients were analyzed. Finally, a bioinformatic analysis was performed to investigate the potential functions of DE genes. Four hundred and fifty-one lncRNAs and 272 mRNAs were DE between the NPSLE patients and Non-NPSLE patients, among which, significantly upregulated expression levels of NONHSAT208182.1, NONHSAT182114.1, NONHSAT106801.2, NONHSAT039491.2, ENST00000356215, NONHSAT087499.2 and NONHSAT207026.1 while downregulated expression levels of NONHSAT001281.2 and NONHSAT024353.2 were further validated in PBMCs from NPSLE patients by qRT-PCR. Bioinformatic analysis suggested several gene ontology (GO) terms and signal pathways may play important roles in NPSLE development. Co-expression networks analysis indicated that 170 lncRNAs and 46 mRNAs were included in the co-expression network. The expression level of NONHSAT039491.2 was associated with the activity of SLE and the presence of anti-dsDNA, anti-RNP antibody, dizziness and headache. NONHSAT087499.2 level correlated with anti-RNA antibody, ENST00000356215 level correlated with olfactory threshold and oral ulcer. NONHSAT208182.1 level correlated with the presence of fever, unstable walking and urinary red blood cells. NONHSAT106801.2 correlated with frequency of B cells and the presence of fever. NONHSAT024353.2 level was associated with serum IgG levels and the presence of anti-SSA and disorder of consciousness. Our data provided comprehensive evidence regarding the differential expression of lncRNAs in PBMCs from NPSLE patients, indicating that these DE lncRNAs may play roles in NPSLE development. Our finding shed light on the understanding of the molecular mechanisms of lncRNAs in the pathogenesis of NPSLE.

Sections du résumé

BACKGROUND BACKGROUND
Long noncoding RNAs (lncRNAs) are emerging as critical regulators of gene expression in the immune system, but their impact on neuropsychiatric systemic lupus erythematosus (NPSLE) remains unknown.
METHODS METHODS
RNA sequencing analysis was used to screen the comprehensive expression profile of lncRNAs and messenger RNAs (mRNAs) in peripheral blood mononuclear cells (PBMCs) from NPSLE patients, active SLE patients who had never experienced neuropsychiatric manifestations (Non-NPSLE) and healthy controls. Differentially expressed (DE) lncRNA levels were validated by qRT-PCR in 26 NPSLE patients, 31 Non-NPSLE patients and 30 healthy controls. Further, correlations of DE lncRNAs with clinical manifestations of NPSLE patients were analyzed. Finally, a bioinformatic analysis was performed to investigate the potential functions of DE genes.
RESULTS RESULTS
Four hundred and fifty-one lncRNAs and 272 mRNAs were DE between the NPSLE patients and Non-NPSLE patients, among which, significantly upregulated expression levels of NONHSAT208182.1, NONHSAT182114.1, NONHSAT106801.2, NONHSAT039491.2, ENST00000356215, NONHSAT087499.2 and NONHSAT207026.1 while downregulated expression levels of NONHSAT001281.2 and NONHSAT024353.2 were further validated in PBMCs from NPSLE patients by qRT-PCR. Bioinformatic analysis suggested several gene ontology (GO) terms and signal pathways may play important roles in NPSLE development. Co-expression networks analysis indicated that 170 lncRNAs and 46 mRNAs were included in the co-expression network. The expression level of NONHSAT039491.2 was associated with the activity of SLE and the presence of anti-dsDNA, anti-RNP antibody, dizziness and headache. NONHSAT087499.2 level correlated with anti-RNA antibody, ENST00000356215 level correlated with olfactory threshold and oral ulcer. NONHSAT208182.1 level correlated with the presence of fever, unstable walking and urinary red blood cells. NONHSAT106801.2 correlated with frequency of B cells and the presence of fever. NONHSAT024353.2 level was associated with serum IgG levels and the presence of anti-SSA and disorder of consciousness.
CONCLUSIONS CONCLUSIONS
Our data provided comprehensive evidence regarding the differential expression of lncRNAs in PBMCs from NPSLE patients, indicating that these DE lncRNAs may play roles in NPSLE development. Our finding shed light on the understanding of the molecular mechanisms of lncRNAs in the pathogenesis of NPSLE.

Identifiants

pubmed: 32355793
doi: 10.21037/atm.2020.03.25
pii: atm-08-06-349
pmc: PMC7186624
doi:

Types de publication

Journal Article

Langues

eng

Pagination

349

Informations de copyright

2020 Annals of Translational Medicine. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form and declare: The authors have no conflicts of interest to declare.

Références

Trends Immunol. 2018 Jan;39(1):55-69
pubmed: 28919048
J Neurol. 2014 Sep;261(9):1706-14
pubmed: 24952022
Rambam Maimonides Med J. 2017 Jan 30;8(1):
pubmed: 28178431
Nat Immunol. 2017 Aug 22;18(9):962-972
pubmed: 28829444
Mol Med Rep. 2018 Mar;17(3):3489-3496
pubmed: 29286106
Clin Exp Rheumatol. 2018 Nov-Dec;36(6):1003-1007
pubmed: 29846157
Sci Rep. 2017 Nov 9;7(1):15119
pubmed: 29123179
J Autoimmun. 2016 Nov;74:118-138
pubmed: 27396525
Lupus. 2016 Aug;25(9):997-1003
pubmed: 26846690
Nat Rev Mol Cell Biol. 2018 Mar;19(3):143-157
pubmed: 29138516
Medicine (Baltimore). 2016 Mar;95(10):e2761
pubmed: 26962774
Open Access Rheumatol. 2016 Dec 20;9:1-9
pubmed: 28053559
Mol Ther Nucleic Acids. 2018 Mar 2;10:269-276
pubmed: 29499939
Nat Immunol. 2015 Mar;16(3):318-325
pubmed: 25621826
J Autoimmun. 2016 Dec;75:96-104
pubmed: 27481557
Autoimmun Rev. 2015 Sep;14(9):798-805
pubmed: 25989481
Arthritis Rheum. 2009 May;60(5):1484-7
pubmed: 19404932
Horm Metab Res. 2016 Aug;48(8):550-7
pubmed: 27214311
Autoimmun Rev. 2018 Apr;17(4):405-412
pubmed: 29444467
Arthritis Rheum. 1999 Apr;42(4):599-608
pubmed: 10211873
Cell Immunol. 2017 Sep;319:17-27
pubmed: 28622785
J Autoimmun. 2016 Nov;74:41-72
pubmed: 27427403
Oncotarget. 2017 Aug 24;8(44):77400-77406
pubmed: 29100395
Front Endocrinol (Lausanne). 2018 Jan 17;9:2
pubmed: 29387042
Arthritis Rheum. 2007 Apr;56(4):1242-50
pubmed: 17393453
Nat Rev Rheumatol. 2017 Nov;13(11):657-669
pubmed: 28978995
Science. 2014 Apr 18;344(6181):310-3
pubmed: 24744378
J Neurol Sci. 2017 Dec 15;383:188-198
pubmed: 29246612
J Autoimmun. 2018 Jul;91:34-44
pubmed: 29627289
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Trends Mol Med. 2018 Mar;24(3):257-277
pubmed: 29449148
Exp Ther Med. 2017 Oct;14(4):3153-3158
pubmed: 28912865
Front Immunol. 2018 Apr 04;9:557
pubmed: 29670611
Nat Rev Rheumatol. 2016 Nov 22;12(12):716-730
pubmed: 27872476
Oncotarget. 2017 Apr 4;8(14):23650-23663
pubmed: 28423570

Auteurs

Linyu Geng (L)

Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Xue Xu (X)

Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Huayong Zhang (H)

Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Chen Chen (C)

Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Yayi Hou (Y)

Institute of Brain Sciences, Medical School, Nanjing University, Nanjing 210093, China.

Genhong Yao (G)

Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Shiying Wang (S)

Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Dandan Wang (D)

Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Xuebing Feng (X)

Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Lingyun Sun (L)

Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Jun Liang (J)

Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Classifications MeSH